Market News AIOpen the app

B. Riley raised its price target for Orchestra BioMed to $12 from $11 and still recommends buying the stock.

OpinionRead the original at marketscreener.com
Good for OBIO

B. Riley raised its target and kept its Buy rating, a favorable analyst signal.

OBIO · Orchestra BioMed Holdings, Inc.

AI read · Good for OBIO

The AI's read

The change shows B. Riley sees slightly more room for Orchestra BioMed shares and kept its Buy rating. The report gives no new sales, trial results, or company forecast, so the support comes only from the firm's opinion.

Get alerts for OBIO

Follow Orchestra BioMed Holdings, Inc. (OBIO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for OBIO
Free on the App Store and Google Play, or on the web.